• Consensus Rating: Buy
  • Consensus Price Target: $10.67
  • Forecasted Upside: 45.32 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.34
▼ -0.03 (-0.41%)

This chart shows the closing price for EDAP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Edap Tms Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDAP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDAP

Analyst Price Target is $10.67
▲ +45.32% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Edap Tms in the last 3 months. The average price target is $10.67, with a high forecast of $11.00 and a low forecast of $10.00. The average price target represents a 45.32% upside from the last price of $7.34.

This chart shows the closing price for EDAP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Edap Tms. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Piper SandlerLower Target$13.00 ➝ $11.00High
11/19/2021B. RileyLower TargetBuy$13.00 ➝ $10.00High
11/19/2021HC WainwrightLower TargetBuy$12.00 ➝ $11.00High
8/27/2021HC WainwrightReiterated RatingBuy$12.00Low
4/28/2021Piper SandlerInitiated CoverageOverweight$13.00Medium
4/1/2021HC WainwrightBoost TargetBuy$10.00 ➝ $12.00Low
1/25/2021Lake Street CapitalInitiated CoverageBuyHigh
1/22/2021B. RileyBoost TargetBuy$11.50 ➝ $13.00Low
1/21/2021HC WainwrightBoost TargetBuy$6.00 ➝ $10.00High
1/12/2021B. RileyBoost TargetBuy$5.50 ➝ $11.50High
11/20/2020HC WainwrightBoost TargetBuy$5.00 ➝ $6.00Low
4/15/2020B. RileyInitiated CoverageBuy$5.50Medium
4/1/2020HC WainwrightLower TargetBuy$6.50 ➝ $5.00Medium
11/15/2019HC WainwrightReiterated RatingBuy$6.50High
8/30/2019HC WainwrightSet TargetBuy$7.00Low
6/11/2019HC WainwrightSet TargetBuy$7.00Medium
5/17/2019HC WainwrightSet TargetBuy$7.00Low
4/3/2019HC WainwrightReiterated RatingBuy$6.50Medium
11/16/2018HC WainwrightReiterated RatingBuy$7.00High
9/4/2018HC WainwrightReiterated RatingBuyLow
7/2/2018HC WainwrightReiterated RatingBuy$6.50Low
5/16/2018HC WainwrightReiterated RatingBuy$6.50Medium
3/29/2018HC WainwrightSet TargetBuy$7.00High
11/22/2017HC WainwrightReiterated RatingBuy$6.50N/A
10/9/2017HC WainwrightReiterated RatingBuy$6.50N/A
8/25/2017HC WainwrightReiterated RatingBuy$6.50High
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/19/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/18/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Edap Tms logo
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Read More

Today's Range

Now: $7.34
Low: $7.31
High: $7.38

50 Day Range

MA: $6.91
Low: $6.25
High: $7.66

52 Week Range

Now: $7.34
Low: $5.00
High: $7.88

Volume

516 shs

Average Volume

27,023 shs

Market Capitalization

$245.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Edap Tms?

The following Wall Street sell-side analysts have issued reports on Edap Tms in the last twelve months: B. Riley, HC Wainwright, Piper Sandler, and StockNews.com.
View the latest analyst ratings for EDAP.

What is the current price target for Edap Tms?

3 Wall Street analysts have set twelve-month price targets for Edap Tms in the last year. Their average twelve-month price target is $10.67, suggesting a possible upside of 45.3%. HC Wainwright has the highest price target set, predicting EDAP will reach $11.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $10.00 for Edap Tms in the next year.
View the latest price targets for EDAP.

What is the current consensus analyst rating for Edap Tms?

Edap Tms currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EDAP will outperform the market and that investors should add to their positions of Edap Tms.
View the latest ratings for EDAP.

What other companies compete with Edap Tms?

Other companies that are similar to Edap Tms include Zynex, Hyperfine, FONAR, Movano and Electromed. Learn More about companies similar to Edap Tms.

How do I contact Edap Tms' investor relations team?

Edap Tms' physical mailing address is Parc d'Activites la Poudrette-Lamartine 4/6 rue du Dauphine, Vaulx-en-Velin I0, 69120. The medical equipment provider's listed phone number is (347) 215-3150 and its investor relations email address is [email protected] The official website for Edap Tms is www.edap-tms.com. Learn More about contacing Edap Tms investor relations.